相关实验视频
Updated: May 20, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.2K
未来是现在:澳大利亚对帕金森病和前进性疾病的疾病修饰试验的观点
Simon Jg Lewis1, Carolyn M Sue2,3, Antony Cooper4
1Macquarie Medical School, Macquarie University, Sydney, New South Wales, Australia.
BMJ neurology open
|March 25, 2025
概括
平台试验正在获得帕金森病研究的引力,使多种治疗方法的并行评估成为可能. 这一观点强调了澳大利亚的举措及其扩展到新西兰,解决成功研究的挑战.
科学领域:
- 神经科学是一个神经科学.
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 研究正在探索改变疾病的治疗方法.
- 平台试验为同时评估多个研究产品提供了一种有效的方法.
- 现有的平台试验计划主要集中在北美和欧洲.
研究的目的:
- 为突出澳大利亚正在进行的帕金森病平台试验工作.
- 讨论这些试验计划扩展到新西兰.
- 应对挑战,并提出解决方案,以在该地区成功实施平台试验.
主要方法:
- 这是一篇观点文章,而不是一项初级研究.
- 它综合了澳大利亚和新西兰当前平台试验活动的信息.
- 它讨论了潜在的后勤,监管和协作挑战.
主要成果:
- 澳大利亚正在开展几项针对帕金森病的平台试验计划.
- 这些试验的战略计划是扩展到新西兰,促进跨塔斯曼的合作.
- 主要挑战包括资金,监管协调和参与者招聘.
结论:
- 澳大利亚已经为帕金森病建立了平台试验,计划扩展到新西兰.
- 解决已识别的挑战对于这些协作,多产品研究的成功至关重要.
- 这些举措代表了该地区帕金森病治疗开发的重大进展.
相关概念视频
Parkinson's Disease: Overview
399
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
399
Parkinson's Disease: Treatment
166
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
166
Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137
Alzheimer's Disease: Overview
399
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
399
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K

